Vitamin K2 (MK-7) and coronary calcium: a described 2-year placebo-controlled trial
Thumbnail from YouTube. Playing loads the YouTube player.
History & recommendationsOff
Keep recently viewed content on this browser. Your history stays on this device and is never sent to Harbor. Videos you play can also help order related video recommendations.
Open saved items & history →At a glance
Automatic summary · not editorially reviewedThe description reports a randomized, placebo-controlled trial in 180 patients with symptomatic coronary artery disease: calcium scores rose in both groups over 2 years, but less on 360 micrograms of MK-7 than on placebo. The creator stresses that a lower score is a surrogate outcome, not proof of fewer heart attacks, strokes or deaths. [1]
The description reports a randomized, placebo-controlled trial of 180 patients with symptomatic coronary artery disease, with 167 in the final analysis and 2 years of MK-7 or placebo. [1]
Calcium scores rose in both groups, from 145 to 214 on placebo and from 135 to 184 on K2, and the difference was described as statistically significant. [1]
The creator says the trial used a surrogate outcome instead of heart attacks, strokes or deaths and calls for a larger study with hard clinical outcomes. [1]
Described trial: 180 patients, MK-7 versus placebo
According to the description, the VitaK-CAC study was a randomized, placebo-controlled trial at 2 hospitals in the Netherlands. It enrolled 180 patients with symptomatic coronary artery disease, and 167 were included in the final analysis. Half took 360 micrograms of MK-7, described as the form of vitamin K2 with the most research behind it, and the rest took a placebo for 2 years. The creator says no significant adverse effects were reported. [1]
Calcium scores rose in both groups, less on K2
The description states that calcium scores rose in both groups: from 145 to 214 on placebo and from 135 to 184 on K2. So no one's plaque disappeared, yet the difference between groups was described as statistically significant, with artery calcium buildup slowed by about 29%. The creator also distinguishes two kinds of coronary calcification: small, patchy specks inside inflamed soft plaque that can raise rupture risk, and dense, solid calcium that often reflects an old injury sealing itself off. A standard calcium scan cannot see soft plaque or wall inflammation, the description adds. [1]
Surrogate outcome and short 2-year follow-up
The creator says the trial could not tell us about heart attacks, strokes or deaths, because it used a surrogate outcome instead. The 2-year length is also described as short, and the authors reportedly still call for a larger study with hard clinical outcomes. The description presents possible mechanisms, such as effects through insulin sensitivity and metabolic inflammation rather than pulling calcium out of arteries, and discusses doses of 300 to 400 micrograms more often than the 100 or 200 micrograms on many labels. These are described as discussion points, not established benefits. [1]
Context & limits
This is based only on the video description; the video and transcript were not reviewed. The description is educational content, not medical advice, and it reports a surrogate outcome over 2 years rather than heart attacks, strokes or deaths. The described mechanisms and dose discussion are not established benefits.
Based on the creator’s description; the full video and transcript were not analyzed.
Quoted passages in the original language
randomized, placebo-controlled trial of 180 patients
from 145 to 214 on placebo
surrogate outcome instead of heart attacks
About this video
Creator description · original textText language: American English
My Longevity Experiment | Vince Cording · 13 min · Source published: 2026-10-09
Added to Harbor: 10/23/2026
Original on YouTube ↗Automatically categorized source. Creator statements are not an independent evidence review or personal medical guidance.